| 3001

FRIDELL Et aL.
Steroid elimination is very appealing in the setting of pancreas transplantation because of their extensive side-effect profile and poor tolerability. [3] [4] [5] [6] In particular, for pancreas transplantation, concerns about insulin resistance and development of type II diabetes mellitus related to steroid therapy have been raised. This was one of the essential components of the Edmonton immunosuppression protocol for Islet transplantation 7 and has been well described in pancreas transplantation. [8] [9] [10] That being said, a two-drug maintenance strategy may be inadequate for PTA. Additionally, although not enough to qualify for kidney transplantation, recipients tend to have some degree of diabetic nephropathy and do not tolerate nephrotoxic medications at full dose. This patient population tends to also consist of particularly brittle diabetics where gastroparesis and other diabetes-related bowel motility disorders may be quite common. For this reason, full-dose mycophenolate mofetil or mycophenolic acid may not be tolerated. A three-drug maintenance strategy permits the simultaneous increase in overall immunosuppression while using lower doses of the individual medications in order to avoid toxicity.
There have been several reports associating development of donor-specific antibody (DSA) with late allograft failure. 11, 12 We have previously reported our liver transplant immunosuppression protocol that included delayed rabbit antithymocyte globulin (rATG) (48-hour delay, three doses for total of 6 mg/kg) and a single dose of rituximab (1.5 mg/m 2 ). 13 Based on this protocol, rituximab was added for all PTA as well in an attempt to decrease development of DSA and hopefully decrease long-term allograft loss to chronic rejection. We have previously reported the impact this has had on development of DSA in this patient population.
14 This study is a retrospective single-center analysis that describes the results using a steroid-free rATG induction protocol with threedrug immunosuppression maintenance therapy, comparing both prior to and following introduction of rituximab as a component of induction.
| MATERIAL S AND ME THODS
The medical records for all adult, deceased-donor PTA transplants performed at Indiana University between January 2004 and September 2017 were reviewed (n = 166). Data were extracted from the comprehensive transplant recipient registry maintained at our center, individual written and electronic medical records, and the original donor medical history. Inclusion criteria for this analysis included all PTA recipients. Pancreas retransplants, even if performed early, were included in this analysis.
All recipients were listed for transplantation at Indiana University according to standard procedures and protocols as established by our own center and the United Network for Organ Sharing (UNOS).
During the study period, in order to qualify for pancreas transplant listing at our institution, the potential recipient had to be insulin dependent with a fasting serum C-peptide level <2 ng/mL. For PTA, the recipients had to demonstrate preserved renal function, usually with a creatinine clearance of at least 50 mL/min/1.73 m 2 .
Pancreas allografts were typically procured using an en-bloc technique following aortic flush with preservation solution and topical cooling with saline slush, as previously described. 15, 16 The recipient operation was performed through a midline incision. The pancreas was routinely positioned with the tail toward the pelvis and the head and duodenum oriented superiorly in order to facilitate the enteric anastomosis. Systemic venous drainage was performed to the vena cava or to the right common iliac vein. Arterial perfusion of the allograft was routinely established from the right common iliac artery, although on rare occasions where this vessel was found to be diseased or had been the site for arterial anastomosis for a prior transplant, the inflow would be established either from the aorta or the left common iliac artery. All pancreas allografts were drained enterically using a stapled technique as described elsewhere. 17 The induction immunosuppression protocol consisted of five doses of rATG (1 mg/kg/dose) and maintenance (initiated postoperative day 1) with tacrolimus (target trough 6-8 ng/mL), sirolimus (target trough 3-6 ng/mL) and mycophenolate mofetil (MMF) (500 mg po bid). 8, 18 Steroids were exclusively used as a premedication for rATG and were discontinued following induction in all recipients. As 
| RE SULTS
From 2004 to 2017, 166 PTA were performed. Donor and recipient demographics are presented in Table 1 . The median follow-up for the entire population was 80 months. Six percent of cases were retransplants. Thirty-one percent of donor recipient combinations were CMV positive to negative (high risk). A prior diagnosis of gastroparesis was noted for 20% of the recipients. Outcomes for the entire PTA patient population are presented in Table 2 . Median length of stay was 7 days and readmissions within the first 3 months was 49% of which 29% were related to dysmotility and dehydration.
Specifically, graft loss at 7 and 90 days were 4% and 5%, respectively and 1-year patient and pancreas allograft survival were 97%
and 91%, respectively. The majority of patients tolerated a threedrug maintenance regimen with calcineurin inhibitor, sirolimus, and either mycophenolate mofetil, mcophenolic acid or azathioprine with only 25 patients (15%) requiring monthly infusion of basiliximab as a third agent. Within the first year, the incidence of infection was 43% (CMV 11%). There were 31 patients treated for rejection (19%), all of which were treated with bolus steroids and with 22 also receiving rATG treatment. Eleven patients were treated more than once for rejection. Five-year pancreas allograft survival was 68%.
Median fasting c-peptide was 2.0 ng/mL with a median HBA1C of 5.5%. In terms of renal function, the median glomerular filtration rate (GFR) prior to transplant was 90 mL/min/ rituximab, there was no significant difference in recipient demographics, although there were significantly more female donors (P = .04) in the rituximab group (Table 1) . Median length of stay was similar at 7 days for both groups. Readmissions within the first 3 months were similar (50% and 49%, for with and without rituximab, respectively) with 26% and 40% being related to dysmotility and dehydraton. There was no significant difference in 7-day (3% vs. 6%) or 90-day (5% vs. 6%) graft loss, 1-year patient (97% in both) or graft (92% vs. 86%, P = .22) survival. Median HBA1C
were similar (5.5% vs. 5.4%) as was median fasting c-peptide levels (2.0 ng/mL in both). The median GFR at baseline was 90 mL/ min/1.73 m 2 in both groups and decreased to 76 and 84 mL/ min/1.73 m 2 at 1 year. In terms of body weight, this remained reasonably stable and was similar between the groups (−1.3 kg and −3.9 kg). There was also no difference in first-year rate of rejection (7% vs. 6%, P = 1) or infection (41% vs. 51%, P = .24) ( Table 2) . Firstyear CMV rates were also comparable at 12% versus 9%, (P = .65) with more recipients in the high-risk donor positive to recipient negative in the rituxan group (33% vs. 26%). Ten-year allograft and patient survival comparing with and without rituximab are shown in Figures 1 and 2 . The differences were not significant (P = .65, .19). As the majority of deaths were with a functioning pancreas allograft (14 of 17), we have also included death-censored pancreas allograft survival, which did not reach significance but did demonstrate further splaying of the survival curves favoring the group that received ritximab (P = .17).
| D ISCUSS I ON
Of all the different varieties of pancreas transplantation, PTA remains the most problematic for several reasons. First, the allograft survival is inferior to all other combinations of pancreas transplantation, including pancreas after kidney transplantation which is also an isolated pancreas allograft. This inferior graft survival is the result of increased early graft loss from technical issues, mostly allograft thrombosis, and from a high rate of late attrition from chronic rejection. Second, the patient population is complicated. Typically, patients present at a younger age compared to recipients that also require a renal transplant. They tend to be more brittle and have a higher incidence of gastrointestinal issues such as gastroparesis and diabetic bowel motility disorders. Finally, although their kidney function has not deteriorated enough to mandate renal transplantation, these patients' kidneys have been exposed to years of diabetes and the function is typically somewhat impaired. Although less common, this patient population also includes patients that have previously undergone total pancreatectomy for nonmalignant diseases, which can represent a very difficult reoperative pancreas transplantation.
With all of these factors combined, although the operation sounds straightforward, this is a physiologically and immunologically complicated recipient population.
The strategy for immunosuppression described here was developed in order to provide increased immunosuppression by combining three nonsteroid agents in order to decrease pancreas allograft attrition to chronic rejection and to minimize individual medication dosing in order to decrease toxicity. Similar approaches applying the same philosophy (although including corticosteroids) have been independently reported. 19 In terms of efficacy, the pancreas allograft short-and long-term survival is superior to This may prove to be a safe and potentially effective approach, but a larger series would be required to demonstrate a significant improvement in allograft survival.
| CON CLUS ION
Rabbit antithymocyte globulin induction and steroid withdrawal followed by a steroid-free three-drug immunosuppression regimen is an excellent strategy for pancreas transplant alone recipients.
Rituximab as a component of induction was well tolerated, though a larger patient population with longer follow-up and specific monitoring for development of DSAs and autoantibodies would be required to determine the full impact. 
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